Publications by authors named "M C Etienne-Grimaldi"
Objectives: Dihydropyrimidine dehydrogenase (DPD) deficiency is the main cause of severe fluoropyrimidine-related toxicities. The best strategy for identifying DPD-deficient patients is still not defined. The EMA recommends targeted genotyping or uracilemia (U) testing.
View Article and Find Full Text PDFThis ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that individual AA concentrations remained constant over treatment time, with no noticeable changes during repeated long-term drug administration for up to 120 days. There was no correlation between AA concentrations and survival outcomes.
View Article and Find Full Text PDFArticle Synopsis
- - Dihydropyrimidine dehydrogenase (DPD) deficiency is a major cause of severe toxic reactions in patients treated with fluoropyrimidine (FP) drugs; a meta-analysis was done to evaluate the effect of specific DPYD gene variants and other clinical factors on predicting severe toxicity.
- - The study focused on Caucasian patients not receiving FP dose adjustments due to DPD deficiency, finding that the prevalence of severe toxicity (G4-5) after 12 weeks was 7.3%, with certain genetic variants notably increasing risk.
- - Significant findings indicate that combining DPYD variant data with clinical characteristics greatly enhances the ability to identify patients at risk for extreme FP-related toxicity, emphasizing the importance of